Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

The Prime Minister’s Citizen Assistance and Relief in Emergency Situations Fund (PM CARES Fund) received Rs 912 crore in contributions during the financial year 2022-23 as donations continued to pour ...

Eli Lilly and Co. said in October it will invest an additional $4.5 billion at its manufacturing site at the LEAP Research and Innovation District in Boone County to create a center for advanced ...

Novo's Ozempic is approved by the U.S. Food and Drug Administration (FDA) to treat diabetes, while Wegovy is primarily prescribed for obesity care. In the same vein, Lilly's Mounjaro is approved ...

That's where my life was going. So when people say 'Why do you care?' That's why I care. Because that's who I am, that's what I'm going to become." On a February 2021 episode of her podcast Empty ...

Eli Lilly announced FDA approval of Zepbound as the first prescription medicine for adults with moderate-to-severe obstructive sleep apnea. In addition, adults on Zepbound lost an average of 45 ...

Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug Administration (FDA) as the first prescription drug to help alleviate moderate ...

We hope this will spark more meaningful conversations between patients and health care providers and ultimately lead to better health outcomes." Eli Lilly expects to launch the drug for OSA at ...

Christmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker’s obesity star Zepbound. With the FDA’s green light on Friday, Lilly’s dual ...

Kennedy Jr. oversee the nation’s health care system. Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third quarter alone ...

Dec 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Eli Lilly's (LLY.N), opens new tab weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. US regulators have approved Eli Lilly’s Zepbound to treat adults with both sleep apnoea and obesity ...